Search clinical trials for: Neisseria gonorrhoeae

Total 505 results

Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Meningococcal Disease

Korea, Republic of
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos

Meningitis, Meningococcal, Serogroup C

Brazil
Pfizer

Completed

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Meningitis, Meningococcal

United States
Novartis Vaccines

Completed

Safety Surveillance of MenACWY-CRM Vaccine in Children

Meningococcal Disease

United States
Novartis Vaccines
Novartis

Completed

A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

Meningococcal Disease | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

Meningococcal Infections | Neisseria Meningitidis

Saudi Arabia
Lanzhou Institute of Biological Products Co., Ltd
Air Force Military Medical University, China

Unknown

A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine

Meningococcal Meningitis

China
University of California, San Diego
National Institute of Mental Health (NIMH)

Completed

Implementation of an Efficacious Intervention for High Risk Women in Mexico

HIV | Chlamydia | Gonorrhea | Syphilis

Mexico
Pfizer

Completed

Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216

Meningococcal Meninigitis, Serogroup C

Austria, Germany
Pfizer

Completed

Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)

Neisseria Meningitidis (Bacterial Meningitis) | Invasive Pneumococcal Disease (IPD)

Germany
Pfizer

Completed

NeisVac-C Single Prime Study in Infants

Neisseria Meningitidis

Poland, Spain
Pfizer

Completed

Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants

Meningitis, Meningococcal

Austria, Germany
North Bronx Healthcare Network

Withdrawn

Project AWARE: Using the Emergency Department (ED) to Prevent Sexually Transmitted Infections (STIs) in Youth (AWARE)

HIV | Chlamydia | Gonorrhea

United States
JN-International Medical Corporation

Completed

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Meningococcal Infections | Meningococcal Meningitis

United States
Pfizer

Completed

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Meningitis, Meningococcal

Poland, Spain, Australia
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Novartis Vaccines

Completed

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

Meningococcal Infections | Meningococcal Meningitis

Argentina, Chile, Czech Republic, Hungary, Italy
Novartis Vaccines
Novartis

Completed

A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults

Meningococcal Disease | Meningococcal Meningitis

Italy
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

Meningococcal Infections

Belgium, Czech Republic, Germany, Italy, Spain, United Kingdom
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
Novartis Vaccines

Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Meningococcal Disease

Austria, Finland, Germany, Italy, Czech Republic
Novartis Vaccines
Novartis

Completed

Safety of MenACWY-CRM Vaccination in Adolescents

Meningococcal Disease

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Meningococcal Disease | Meningococcal Meningitis

Australia, Canada
Sanofi Pasteur, a Sanofi Company

Completed

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Meningitis | Meningococcal Disease

United States
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Meningococcal Disease | Meningococcal Meningitis

Spain, Italy, United Kingdom, Czech Republic
University of Zurich

Completed

Colonization of the Female Urethra With Mycoplasma Hominis, Ureaplasma Urealyticum, Chlamydia Trachomatis, or Neisseria Gonorrhea in Patients With Lower Urinary Tract Symptoms

Overactive Bladder Syndrome

Switzerland
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Infections, Meningococcal

United States
Pfizer

Terminated

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

Meningitis, Meningococcal

Spain
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

Meningococcal Disease | Meningococcal Meningitis

Chile, Colombia, Panama
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

Meningitis | Meningococcal Disease

Philippines
Leiden University Medical Center

Completed

Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines

Meningococcal Disease

Netherlands
Novartis Vaccines
Novartis

Completed

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Meningococcal Disease

Canada, United Kingdom
Novartis Vaccines
Novartis

Completed

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Meningococcal Disease

United Kingdom
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Competitive Carriage of Neisseria Spp(Lactamica 2) (Lactamica 2)

Neisseria Lactamica

United Kingdom
Novartis Vaccines

Completed

Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

Prevention of Meningococcal Infection

United Kingdom
Novartis
Novartis Vaccines

Completed

Kinetics of B Cell Response in Infants Menjugate Vaccination

Prevention of Meningococcal Infection

United Kingdom
Novartis
Novartis Vaccines

Completed

Persistence of Immune Response After Vaccination With MCC

Prevention of Meningococcal Infection

United Kingdom
University Hospital, Rouen
Institut Pasteur; Direction Générale de la Santé, France

Completed

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC) (Exten Effivac)

Neisseria Meningitidis

France
University Hospital, Rouen
Institut Pasteur; Direction Générale de la Santé, France; Dieppe

Completed

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac) (Exten MenbVac)

Vaccination With MenbVac

France
Novartis Vaccines

Completed

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Meningococcal Disease

United States, Ukraine
University of California, Los Angeles
National Institute of Mental Health (NIMH); Asociación Civil Impacta Salud...

Completed

Expedited Partner Therapy for MSM in Peru

Chlamydia | Gonorrhea

Peru
Novartis Vaccines

Completed

Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years

Meningococcal Disease | Meningococcal Meningitis

Italy
Novartis Vaccines
Novartis

Completed

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

Prevention of Meningococcal Disease

Canada, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children

Meningitis | Meningococcal Disease

China
Novartis Vaccines

Completed

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

Meningococcal Disease

United States, Australia, Canada
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults

Meningococcal Infections | Meningococcal Meningitis

Argentina, Colombia

3

Subscribe